Derek M. Meisner - 06 Mar 2026 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Reporting relationship: Chief Legal Officer & Corp Sec
Issuer ticker: ABOS
Reported as of: 06 Mar 2026
Net transaction value: -$6,813
SEC form: 4
Accepted by SEC: 10 Mar 2026, 21:45:26 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Derek Meisner

Key filing fact

Derek M. Meisner filed Form 4 for Acumen Pharmaceuticals, Inc. (ABOS) on 10 Mar 2026.

Key facts

This page summarizes Derek M. Meisner's Form 4 filing for Acumen Pharmaceuticals, Inc. (ABOS).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Mar 2026, 21:45.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: -$6,813.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001752461 Primary reporting owner

Meisner Derek M

Relationship: Chief Legal Officer & Corp Sec
Address: C/O ACUMEN PHARMACEUTICALS, INC., 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON
Signature: /s/ Derek Meisner
Signature date: 10 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABOS transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,090
Change %: +1.2%
Price: $1.85^*
Shares after: 176,089
Date: 06 Mar 2026
Ownership: Direct

ABOS transaction

Common Stock

Sale

Transaction value: $6,813
Shares: -2,090
Change %: -1.2%
Price: $3.26
Shares after: 173,999
Date: 06 Mar 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABOS transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value
Shares: -2,090
Change %: -2.9%
Price: $0.000000^*
Shares after: 71,048
Date: 06 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,090
Exercise price: $1.85
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

The reported sales occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 29, 2025.

Footnote F2

The shares subject to the option will vest in 48 equal monthly installments such that the option is fully vested on the fourth anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date.